Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EBITDA: 2019-2025

Historic EBITDA for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$145.2 million.

  • BridgeBio Pharma's EBITDA rose 24.28% to -$145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$609.9 million, marking a year-over-year decrease of 12.04%. This contributed to the annual value of -$593.0 million for FY2024, which is 2.37% up from last year.
  • Per BridgeBio Pharma's latest filing, its EBITDA stood at -$145.2 million for Q3 2025, which was down 8.13% from -$134.3 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year EBITDA high stood at $343,000 for Q1 2024, and its period low was -$226.0 million during Q4 2024.
  • Moreover, its 3-year median value for EBITDA was -$146.1 million (2023), whereas its average is -$144.0 million.
  • Per our database at Business Quant, BridgeBio Pharma's EBITDA surged by 100.27% in 2024 and then crashed by 30,529.15% in 2025.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's EBITDA stood at -$165.6 million in 2021, then increased by 21.97% to -$129.2 million in 2022, then plummeted by 37.28% to -$177.4 million in 2023, then fell by 27.40% to -$226.0 million in 2024, then rose by 24.28% to -$145.2 million in 2025.
  • Its EBITDA stands at -$145.2 million for Q3 2025, versus -$134.3 million for Q2 2025 and -$104.4 million for Q1 2025.